CompletedNCT06316973
A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants
Medication studyAges 18–55United StatesAddiction
Understand this study
Who was this study for?
This study was for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Overland ParkSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: February 7, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 32
- Sponsor
- Clear Scientific, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT06316973
- Official title
Show the full official title
A Phase 1a, Randomized, Double-Blind, Placebo-Controlled, Single Center Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CS-1103 Following Single, Ascending Intravenous Dose Administration in Healthy Participants
Recruitment & locations
CompletedOverland Park
Questions about this study
Who is behind this study?
The study sponsor is Clear Scientific, Inc.
Did this study involve medication?
Yes. The study involved medication, including CS-1103 and Sterile Saline.
Who was this study for?
This study was for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Explore HopeStage studies by mental health topic and refine the results to suit your situation.
Find a study that may fit me